Partha Chowdhury
Overview
Explore the profile of Partha Chowdhury including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lan X, Mi T, Alli S, Guy C, Djekidel M, Liu X, et al.
Nat Immunol
. 2024 May;
25(6):1046-1058.
PMID: 38816618
The durability of an antitumor immune response is mediated in part by the persistence of progenitor exhausted CD8 T cells (Tpex). Tpex serve as a resource for replenishing effector T...
2.
Chowdhury P, Lu Z, Su S, Liu M, Lin C, Wang M, et al.
Adv Healthc Mater
. 2024 Apr;
13(20):e2400606.
PMID: 38683681
Emerging organic molecules with emissions in the second near-infrared (NIR-II) region are garnering significant attention. Unfortunately, achieving accountable organic emission intensity over the NIR-IIa (1300 nm) region faces challenges due...
3.
Poltash M, Srzentic K, Beil E, Gorre E, Damoc E, Mahan A, et al.
J Am Soc Mass Spectrom
. 2023 Nov;
34(12):2654-2661.
PMID: 37922506
Multispecific antibody constructs are quickly becoming more common constructs in biopharmaceuticals to improve specificity and efficacy. While the advent of this technology has led to improved therapeutics, its development has...
4.
Boucher L, Prinslow E, Feldkamp M, Yi F, Nanjunda R, Wu S, et al.
MAbs
. 2023 Apr;
15(1):2195517.
PMID: 37074212
Single-chain fragment variable (scFv) domains play an important role in antibody-based therapeutic modalities, such as bispecifics, multispecifics and chimeric antigen receptor T cells or natural killer cells. However, scFv domains...
5.
Pan H, Wu C, Lin C, Hsu C, Tsai Y, Chowdhury P, et al.
J Am Chem Soc
. 2022 Dec;
145(1):516-526.
PMID: 36562565
Organic molecules having emission in the NIR(II) region are emergent and receiving enormous attention. Unfortunately, attaining accountable organic emission intensity around the NIR(II) region is hampered by the dominant internal...
6.
Zwolak A, Chan S, Harvilla P, Mahady S, Armstrong A, Luistro L, et al.
Sci Rep
. 2022 Nov;
12(1):20538.
PMID: 36446890
TL1A (TNFSF15) is a TNF superfamily ligand which can bind the TNFRSF member death receptor 3 (DR3) on T cells and the soluble decoy receptor DcR3. Engagement of DR3 on...
7.
White I, Tamot N, Doddareddy R, Ho J, Jiao Q, Harvilla P, et al.
MAbs
. 2021 Oct;
13(1):1987180.
PMID: 34693867
The global health crisis and economic tolls of COVID-19 necessitate a panoply of strategies to treat SARS-CoV-2 infection. To date, few treatment options exist, although neutralizing antibodies against the spike...
8.
Bosco E, Christie R, Carrasco R, Sabol D, Zha J, DaCosta K, et al.
Oncotarget
. 2018 May;
9(33):22960-22975.
PMID: 29796165
Despite recent advances in treatment, breast cancer remains the second-most common cause of cancer death among American women. A greater understanding of the molecular characteristics of breast tumors could ultimately...
9.
Xiao Z, Carrasco R, Schifferli K, Kinneer K, Tammali R, Chen H, et al.
Mol Cancer Ther
. 2016 Feb;
15(4):689-701.
PMID: 26880266
HER3/ERBB3 is a kinase-deficient member of the EGFR family receptor tyrosine kinases (RTK) that is broadly expressed and activated in human cancers. HER3 is a compelling cancer target due to...
10.
Wu Y, Liu X, Chen Y, Woods R, Lee N, Yang H, et al.
J Pharm Biomed Anal
. 2013 Aug;
86:73-81.
PMID: 23988731
To address a possible linkage between the occurrence of the hypersensitivity reactions and the induction of IgE anti-drug-antibodies (ADA), a drug specific IgE ADA assay was developed using electrochemiluminescence (ECL)...